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Dermatological conditionsAbstract Antihistamines are a group of medications which can inhibit various histaminic actions
at one of two histamine receptors (H1 or H2). H1 receptor antagonists are used for the relief of
allergic dermatological and nondermatological conditions. We will review classes of antihistamines
(H1 antagonists) and the relationship between speciﬁc antihistamines and speciﬁc birth defects.
Although many ﬁndings provide reassurance about the relative safety of many antihistamine drugs
and that any malformation reported is most probably caused by chance, studies are still required to
assure fetal safety. As pruritus is sometimes troublesome for pregnant women topical medications
like emollients should be tried ﬁrst in the ﬁrst trimester of pregnancy. Also pregnant women should
be advised to consult their health care provider before taking any medication.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Antihistamines are a group of medications which possess the
ability to inhibit various histaminic actions. Histamine is
released by our body during an allergic reaction and acts on
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tamine – receptor interaction through competition with his-
tamine for histamine receptors. Thus they prevent and not
reverse histamine actions. Antihistaminic drugs inhibit the
action of histamine at one of the two histamine receptors
(H1 or H2) but not at both receptors. H2 receptor inhibitors
inhibit histamine induced gastric secretion and so are used to
treat gastric ulceration [1]. H1 receptor inhibitors are used
for the relief of allergic dermatological and nondermatological
conditions [2].
Pruritus is one of the most common dermatological symp-
toms during pregnancy [3], whether due to speciﬁc dermatoses
of pregnancy or due to atopic dermatitis, urticaria, angioe-
dema, infections, drug induced or due to various systemic dis-
eases [4].
Also antihistamines can be used for the relief of allergic
rhinitis, allergic conjunctivitis, upper respiratory tract infec-
tions as well as the treatment of pregnancy symptoms of nau-
sea and vomiting, motion sickness, dizziness and insomnia [5].
The antihistamine use during pregnancy ranges from 4 to 10%
during the ﬁrst trimester and from 8 to 15% at any time during
pregnancy in various studies [6,7]. Some antihistamines require
a prescription, but most are available over the counter (OTC).
They are among the most commonly used drugs during preg-
nancy [8].
Several studies have indicated an association between the
maternal use of some antihistamines during early months of
pregnancy and some birth defects [9]. In 1960 Bendectin (con-
taining doxylamine and dicyclomine hydrochloride) which is
commonly used at that time as antinausea preparation was
suspected to be associated with congenital malformations.
Although it is pulled from the market in the years following,
the rate of birth defects remained stable [10].
We will review classes of antihistamines (H1 antagonists)
and the relationship between speciﬁc antihistamines and speci-
ﬁc birth defects if reported in literature.
2. Classiﬁcation of H1 antihistamines
They are classiﬁed as older or 1st generation, 2nd and 3rd gen-
eration antihistamines targeting histamine – type 1 (H1)
receptors.
2.1. First generation histamine H1 receptor antagonists include
[11]:
1- Ethylene diamines which are the ﬁrst group of clinically
effective H1 antihistamines. This class includes
Mepyramine, Antazoline and Tripelennamine.
2- Ethanolamines which has signiﬁcant anticholinergic side
effects and sedation with reduced gastro-intestinal side
effects. This class also includes Diphenhydramine
(Benadryl), Carbinoxamine (Clistine), Doxylamine,
Clemastine (Tavist), Dimenhydrinate (Dramamine),
Orphenadrine and Bromazine.
3- Alkylamines which have fewer sedative and gastroin-
testinal adverse effects, but greater incidence of CNS
stimulation. This class includes Brompheniramine
(Dimetane), Triprolidine, pheniramine (Avil),
Dexchlorpherniramine, Chlorpheniramine (Chlor-
trimeton) Dexbrompheniramine, and Cimetidine.4- Piperazines which have signiﬁcant anticholinergic
adverse effects. Compounds from this group are often
used for motion sickness, vertigo, nausea and vomiting
as Cyclizine, Chlorcyclizine, Hydroxyzine, Meclizine,
[12].
5- Tricyclics and tetracyclics which are structurally related
to tricyclic & tetracyclic antidepressants, explains why
they have cholinergic side effects. This class includes
promethazine (phenergan), Alimemazine (vallergan),
Cyproheptadine, Azatadine (Optimine or Trinalin) and
Ketotifen (Zaditor) [13].
This group (ﬁrst generation antihistamines) has a very
potent effect but are short acting as they have poor selectivity
for H1 receptors and they cross the blood brain barrier. They
have also anticholinergic activity. They are metabolized in the
liver. They have many adverse side effects mostly due to CNS
depression (sedation, dizziness, tinnitus, blurred vision, eupho-
ria, incoordination, anxiety, insomnia, tremors, nausea and
vomiting, dryness of the mouth, constipation, blurred vision,
dry cough, and urinary retention [14].
 FDA classiﬁed antihistamines into:
Category A: A risk to the fetus has not been demonstrated
in controlled studies in women in the ﬁrst trimester and there is
no evidence of risk in later trimester and the possibility of fetal
harm appears remote e.g. cyproheptadine [7].
Category B: A fetal risk has not been demonstrated in ani-
mal studies and no controlled studies in pregnant women have
been done or there are some adverse effects in animal studies
that were not conﬁrmed in controlled studies in women in ﬁrst
trimester e.g. Chlorpheniramine, Diphenhydramine,
Dexchlorpheniramine, Clemastine and Tripelennamine, [15].
Category C: Animal reproductive studies have shown
adverse effects on the fetus and there are no well controlled
studies in humans e.g. Promethazine and Hydroxyzine [15].
Seto et al. [16] and Gilbert et al. [17], reported no increased
fetal risks or birth defects from this class (1st generation anti-
histamines) of drugs when used during any time of pregnancy.
The same was also reported with a meta-analysis which
involved more than 200,000 women in early pregnancy [18].
However Hydralazine was linked to cleft palate [19,20], cleft
lip with or without cleft palate, neural tube defects, spina
biﬁda, limb reduction defects and gastroschisis [18]. Also
chlorpheniramine was linked to eye and ear defects, spina
biﬁda and cleft lip with or without cleft palate [18,19].
Doxylamine was also linked to oral clefts [21], pyloric stenosis,
[22,23], hypoplastic left heart syndrome, spina biﬁda and neu-
ral tube defects[18]. Bendectin (an antinausea preparation con-
taining doxylamine succinate, dicyclomine hydrochloride and
pyridoxine hydrochloride) used in early pregnancy was mini-
mally associated with congenital heart [24].
Also an increased risk of retrolental ﬁbroplasias was
reported in 21% of premature infants exposed in utero to
Diphenhydramine during the last 2 weeks of pregnancy com-
pared to 11% in premature infants not exposed [19]. Also
Diphenhydramine use in early pregnancy was also reported
in relation to cleft palate, cleft lip with or without cleft palate,
neural tube defects, spina biﬁda, limb reduction defects and
gastroschisis [18,19]. Diphenhydramine has also an oxytocin
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2.2. Second generation histamine H1 receptor antagonists:
These are the newer drugs and they are long acting with high
selectivity for the peripheral H1 receptors involved in allergies
as opposed to H1 receptors in the central nervous system. They
are also less lipophilic than ﬁrst generation drugs and do not
cross the Blood Brain Barrier (BBB). Therefore these drugs
provide the same relief with less sedation and performance
impairment [26].
These drugs also have an anti-inﬂammatory activity which
can help in the treatment of inﬂammation in allergic airway
disease [27]. Rare side effects of second generation antihistami-
nes include photosensitivity, tachycardia and prolongation of
QT interval [28].
This class includes Loratadine Acrivastine (Semprex-D),
Terfenadine (Seldane), Azelastine (Astellin or Optivar),
Levocabastine (Livostin), Olopatadine (Patanol), and
Cetirizine (Zyrtec) [29].
2.3. Third generation histamine H1 receptor antagonists:
These drugs are derived from second generation antihis-
tamines. They are either the active enantiomer or metabolite
of 2nd generation drugs designed to increase the efﬁcacy of
the drugs with lesser side effects [30].
This class includes levocetirizine (Xyzal), which is the active
form of cetirizine, Desloratadine (Clarinex), the active metabo-
lite of loratadine, Fexofenadine (Allegra) which is developed as
an alterative to Terfenadine with a decreased risk of cardiac
arrhythmia [13]. However there is some controversy associated
with the use of the term third generation antihistamines [30].
So these drugs will be referred to in this review as 2nd gener-
ation antihistamines [31].
FDA categorized Fexofenadine, Desloratadine as preg-
nancy category C, while Cetirizine, Loratadine and
Levocetirizine as category B [15].
Based on the available pregnancy data Cetirizine is unlikely
to increase the incidence of major or minor malformations in
neonates. There are also no signiﬁcant differences in miscar-
riage or birth rate with ﬁrst trimester exposure [32,33].
However additional studies on larger number of pregnancies
are still needed [32]. Although sedation of Cetirizine is dose
dependent, it is less than that of ﬁrst generation antihistami-
nes, but more sedating than Loratadine or Fexofenadine [34].
Loratadine is the most studied 2nd generation antihis-
tamine and there is no reported increased risk of major malfor-
mations when used in early pregnancy. However some cases of
hypospadias were reported with the use of this drug in early
pregnancy [7,35,36]. The majority of infants had mild glandu-
lar hypospadias which makes the association with early preg-
nancy use of this drug questionable [37]. Also animal studies
did not support this association as McIntyre [38] reported no
increase in the incidence of hypospadias or other androgen
mediated end points in animals that are given up to 120 times
the human dose. At the same time several studies in humans
reported no association between loratadine and desloratadine
and hypospadias, premature delivery or still birth [7,35].
However both drugs are still considered as category B drugsby FDA and performance impairment has been reported with
higher than the recommended doses [39].
No major malformations were reported in infants whose
mothers had taken Fexofenadine in their early pregnancy
although one case of positional talipus was reported which is
unlikely to be caused by the drug [40]. Also reduction in pup
weight and survival was observed in rat pups with this drug.
It is to be noted that this drug is no longer available in some
countries’ markets owing to the clinically signiﬁcant QT pro-
longation [2] Fexofenadine is a metabolite of Terfenadine.
As regards Terfenadine, the Swedish Medical Birth Registry
reported no higher rates of congenital anomalies in neonates
of pregnant women treated with it than in the general popula-
tion [6]. However birth weight of infants was also reported to
be less than 10th percentile for gestational age [41]. On the
other hand animal studies by the manufacturer have not
shown an increase in birth defects in up to 30 times the human
dose [42] although rat pups had dose related decreased weight
gain and survival. Additional studies are needed to clarify if
this drug causes a decrease in birth weight or not.
We have to consider that most pregnancies are unplanned
and the fetus is vulnerable to drug induced teratogenesis from
the day a woman’s period is due [8].
Also we have to consider the popular use of antihistamines
during pregnancy and that most of them are available without
prescription and even a small increase in the risk of speciﬁc
birth defects may have considerable clinical and public health
implications. In Egypt no deﬁnite guidelines have been given
by the government (Health Ofﬁcials) for the use of antihistami-
nes as over the counter medicine or prescription purposes, so
we advice practitioners to follow FDA criteria.
Although no deﬁnite teratogenic effects have been associ-
ated with the intake of antihistamines during pregnancy and
they are not licensed by FDA as category A or safe drugs,
much investigations are still required to prove fetal safety of
these drugs. Women should also be advised to consult their
health care provider before taking any medication.
As pruritus is sometimes troublesome for pregnant women
in the ﬁrst trimester of pregnancy, topical medications like
emollients should be tried ﬁrst together with drinking plenty
of water to overcome anticholinergic side effects. If antihis-
tamines have to be prescribed, ﬁrst generation agents have to
be given as they are relatively safe and well studied [4].
Also the National Asthma Education and prevention pro-
gram recommended the use of 1st generation antihistamines
as chlorpheniramine and tripelennamine due to reassuring ani-
mal and human studies [43]. However in allergic rhinitis and its
impact on Asthma (ARIA) guidelines recommends that ﬁrst-
generation antihistamines should no longer be prescribed
because of poor selectivity and their sedative and anticholiner-
gic effects [44].
If a 2nd generation antihistamine has to be used loratadine
or cetirizine should be preferred as they are categorized as cat-
egory B and they are preferably used after the ﬁrst trimester.
3. Conclusion and recommendations
While many ﬁndings provide reassurance, about the relative
safety of many of these antihistamines and any malformation
reported is most probably caused by chance, studies are still
required to assure fetal safety. Efﬁcacy of the agent should also
290 R.M. Shawky, N.S. Seifeldinbe considered to assure optimal well-being of both the mother
and her infant.
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